EP1011608A4 - Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments - Google Patents

Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments

Info

Publication number
EP1011608A4
EP1011608A4 EP99930160A EP99930160A EP1011608A4 EP 1011608 A4 EP1011608 A4 EP 1011608A4 EP 99930160 A EP99930160 A EP 99930160A EP 99930160 A EP99930160 A EP 99930160A EP 1011608 A4 EP1011608 A4 EP 1011608A4
Authority
EP
European Patent Office
Prior art keywords
ards
cardiopulmonary
ischemia
administration
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930160A
Other languages
German (de)
English (en)
Other versions
EP1011608A2 (fr
Inventor
Jonathan W Nyce
Jeffrey L Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenesis Pharmaceuticals Inc
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Publication of EP1011608A2 publication Critical patent/EP1011608A2/fr
Publication of EP1011608A4 publication Critical patent/EP1011608A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP99930160A 1998-06-08 1999-06-08 Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments Withdrawn EP1011608A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8850198P 1998-06-08 1998-06-08
US88501P 1998-06-08
US8865798P 1998-06-09 1998-06-09
US88657P 1998-06-09
US93972 1998-06-09
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
PCT/US1999/012775 WO1999063938A2 (fr) 1998-06-08 1999-06-08 Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments

Publications (2)

Publication Number Publication Date
EP1011608A2 EP1011608A2 (fr) 2000-06-28
EP1011608A4 true EP1011608A4 (fr) 2002-05-15

Family

ID=27375993

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930160A Withdrawn EP1011608A4 (fr) 1998-06-08 1999-06-08 Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments

Country Status (4)

Country Link
EP (1) EP1011608A4 (fr)
AU (1) AU4675699A (fr)
CA (1) CA2316994A1 (fr)
WO (1) WO1999063938A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2400206A1 (fr) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Procede d'identification et d'utilisation d'antagonistes du recepteur d'adenosine a2b pour agir sur la proliferation cellulaire d'un mammifere
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
EP1434782A2 (fr) 2001-10-01 2004-07-07 University of Virginia Patent Foundation Analogues de 2-propynyle adenosine presentant une activite agoniste de a2a et compositions en contenant
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CN101076343A (zh) 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
WO2007092372A1 (fr) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Procede de preparation d'un agoniste de recepteur a2a-adenosine et ses polymorphes
JP2009541354A (ja) * 2006-06-22 2009-11-26 シーブイ・セラピューティクス・インコーポレイテッド 虚血の治療におけるａ２ａアデノシン受容体アゴニストの使用
CA2718520C (fr) 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification des micro-arn dans l'entretien et la regeneration de synapses neuromusculaires

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040162A1 (fr) * 1995-06-07 1996-12-19 East Carolina University Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040162A1 (fr) * 1995-06-07 1996-12-19 East Carolina University Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NYCE J W ET AL: "DNA ANTISENSE THERAPY FOR ASTHMA IN AN ANIMAL MODEL", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 385, 20 February 1997 (1997-02-20), pages 727 - 725, XP000891493, ISSN: 0028-0836 *
NYCE J W: "Insight into adenosine receptor function using antisense and gene-knockout approaches", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 2, February 1999 (1999-02-01), pages 79 - 83, XP004157301, ISSN: 0165-6147 *
See also references of WO9963938A3 *

Also Published As

Publication number Publication date
WO1999063938A3 (fr) 2000-01-27
WO1999063938A2 (fr) 1999-12-16
WO1999063938A9 (fr) 2000-03-02
AU4675699A (en) 1999-12-30
EP1011608A2 (fr) 2000-06-28
CA2316994A1 (fr) 1999-12-16

Similar Documents

Publication Publication Date Title
EP1011608A4 (fr) Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments
ZA962536B (en) Pharmaceutical composition for transdermal administration.
AU2001253167A1 (en) System and methods for group retirement plan administration
ITRM910922A0 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e metodo per applicarla.
AU3494695A (en) System for electrolyzing fluids for in vivo administration to humans and other warm blooded mammals
AU1632601A (en) System and method for pharmacy administration
DK1181027T3 (da) Diætetisk eller farmaceutisk præparat til anvendelse til forebyggelsen eller behandling af hyperoxaluri
HUP0003121A3 (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
NO20013566D0 (no) Farmasöytisk preparat med regulert frigjöringsvirkning
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
HUP9901779A3 (en) Modified release multiple-units dosage composition
CA2253593A1 (fr) Prevention et traitement du cancer colorectal par l'acide 6-fluoro-ursodesoxycholique (6-fudca)
AU1585601A (en) Transdermal administration of huperzine
ZA99104B (en) Method for administering ASPB28-human insulin.
EP1101482A4 (fr) Aiguille de securite, aiguille placebo et jeu d'aiguilles pour methode en double aveugle
HUP9901794A3 (en) Administration regimen of h+,k+-atpase inhibitors
IS4907A (is) Nýjar bensímídasólafleiður sem vinna gegn magasári, aðferðir til að útbúa þær og lyfjablöndur sem innihalda þær
HUP0104307A3 (en) Pharmaceutical composition for modified release insulin sensitiser
WO1999021574A3 (fr) Amelioration d'activite morphogene
HK1027510A (en) Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
NO20012518L (no) Fremgangsmåte ved fremstilling av legemidler i fast administrasjonsform
AP2003002874A0 (en) Echinocandin derivatives, preparation method and application as anti-fungal agents.
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
FI19991811L (fi) Menetelmä ja järjestelmä varmuuskopiointiin
ZA200006732B (en) Utilization of Aryl (or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000330

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 07H 21/04 B, 7C 07H 21/00 B, 7C 12N 5/00 B, 7C 12N 15/63 B, 7C 12N 15/79 B, 7C 12N 15/09 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 07H 21/00 B, 7C 07H 21/04 B, 7C 12N 5/00 B, 7C 12N 15/63 B, 7C 12N 15/79 B, 7C 12N 15/09 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020328

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050401

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1027510

Country of ref document: HK